Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

WGS

GeneDx Holdings Corp

Sep 12 • 04:00PM ET

123.95

-1.94 -1.54 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH QDEL NTRA EXAS MYGN TWST CDNA CRSP VERV

| Held by: VTI IWM ARKK VXF IWO FESM SCHA VTWO ARKG VHT

Scroll to Statements

Index	RUT	P/E	6628.34	EPS (ttm)	0.02	Insider Own	12.36%	Shs Outstand	28.71M	Perf Week	-6.48%
Market Cap	3.56B	Forward P/E	50.01	EPS next Y	2.48	Insider Trans	-13.87%	Shs Float	25.18M	Perf Month	0.68%
Enterprise Value	3.54B	PEG	47.32	EPS next Q	0.41	Inst Own	108.62%	Short Float	14.43%	Perf Quarter	86.76%
Income	1.41M	P/S	9.83	EPS this Y	606.42%	Inst Trans	8.93%	Short Ratio	4.29	Perf Half Y	38.77%
Sales	362.32M	P/B	12.84	EPS next Y	38.07%	ROA	0.33%	Short Interest	3.63M	Perf YTD	61.27%
Book/sh	9.65	P/C	26.46	EPS next 5Y	140.08%	ROE	0.60%	52W High	136.00 -8.86%	Perf Year	268.13%
Cash/sh	4.68	P/FCF	4290.46	EPS past 3/5Y	70.39% 96.65%	ROIC	0.36%	52W Low	34.94 254.70%	Perf 3Y	254.35%
Dividend Est.	-	EV/EBITDA	116.59	Sales past 3/5Y	12.91% 14.24%	Gross Margin	62.08%	Volatility	4.19% 4.69%	Perf 5Y	-
Dividend TTM	-	EV/Sales	9.78	EPS Y/Y TTM	100.75%	Oper. Margin	1.86%	ATR (14)	5.83	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.70	Sales Y/Y TTM	48.70%	Profit Margin	0.39%	RSI (14)	55.07	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	2.87	EPS Q/Q	133.15%	SMA20	-1.82%	Beta	2.09	Target Price	123.75
Payout	-	Debt/Eq	0.42	Sales Q/Q	45.63%	SMA50	15.98%	Rel Volume	0.36	Prev Close	125.89
Employees	1000	LT Debt/Eq	0.40	Earnings	Jul 29 BMO	SMA200	40.84%	Avg Volume	846.44K	Price	123.95
IPO	Nov 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	331.78% 20.18%	Trades		Volume	311,947	Change	-1.54%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-09-25	Initiated	Piper Sandler	Overweight	$110
May-15-25	Initiated	Guggenheim	Buy	$88
May-09-25	Upgrade	Jefferies	Hold → Buy	$80
Aug-28-24	Initiated	Wells Fargo	Equal Weight	$34
Jul-10-24	Initiated	Craig Hallum	Buy	$43
Jun-03-24	Resumed	Jefferies	Hold	$21

Sep-12-25 02:13PM	Here's Why Pediatrix Medical Shares Are Attracting Investors Now (Zacks)
Sep-05-25 04:16PM	ZoomInfo, International Money Express, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-28-25 08:14AM	PAHC Stock Surges on Q4 Earnings & Revenue Beat, Gross Margin Down (Zacks)
Aug-21-25 10:12AM	Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges (Zacks)
Aug-19-25 09:48AM	MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up (Zacks)
08:22AM	Loading…
Aug-13-25 08:22AM	Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand (Zacks) +5.76%
Aug-12-25 08:27AM	EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up (Zacks) +5.31%
08:25AM	Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise (Zacks)
08:22AM	EYE Stock Gains on Q2 Earnings and Revenue Beat, '25 View Up (Zacks)
08:21AM	VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up (Zacks)
Aug-11-25 12:20PM	Will GENEDX HOLDINGS (WGS) Gain on Rising Earnings Estimates? (Zacks) +5.15%
08:27AM	Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract (Zacks)
07:53AM	TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up (Zacks)
Aug-08-25 12:44PM	Hims Stock Gets Booted Off IBD 50 While Other Volatile Names Hang On (Investor's Business Daily)
08:47AM	TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market (Zacks)
09:55AM	Loading…
Aug-07-25 09:55AM	Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross? (Zacks)
Aug-06-25 09:05AM	Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls (Zacks)
08:30AM	GeneDx to Participate in Upcoming Investor Conferences (Business Wire)
Aug-04-25 09:55AM	IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand (Zacks) +6.64%
Aug-01-25 07:51AM	Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb (Zacks)
Jul-31-25 04:05PM	OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
07:59AM	Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down (Zacks)
Jul-30-25 08:00PM	Why GeneDx Holdings Stock Crushed It Again Today (Motley Fool) +12.78%
Jul-29-25 07:13PM	Why GeneDx Holdings Stock Blasted 8% Higher Today (Motley Fool) +8.09%
09:49AM	WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View (Zacks)
08:54AM	Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang? (Zacks)
07:40AM	GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Beat Estimates (Zacks)
06:30AM	GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Jul-28-25 12:41PM	Baxter Q2 Preview: Can Core Segments Deliver Another Solid Quarter? (Zacks) +6.36%
12:38PM	Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings? (Zacks)
12:10PM	Loading…
12:10PM	Why GENEDX HOLDINGS (WGS) Could Beat Earnings Estimates Again (Zacks)
09:27AM	Earnings To Watch: GeneDx Holdings Corp (WGS) Reports Q2 2025 Result (GuruFocus.com)
09:26AM	Will Exome and Genome Growth Boost WGS' Q2 Earnings? (Zacks)
07:56AM	IDEXX to Release Q2 Earnings: What's in Store for the Stock? (Zacks)
Jul-24-25 11:11AM	Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat? (Zacks)
10:15AM	Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact? (Zacks)
Jul-23-25 10:00AM	Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-22-25 12:11PM	WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up? (Zacks)
10:00AM	GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-21-25 08:05AM	DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance? (Zacks)
Jul-17-25 09:55AM	Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect? (Zacks)
Jul-16-25 09:42AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
Jul-15-25 09:02AM	Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings? (Zacks)
Jul-11-25 08:02AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks) -5.01%
Jul-10-25 08:30AM	GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025 (Business Wire) -5.41%
08:19AM	Here's Why You Should Retain CONMED Stock in Your Portfolio for Now (Zacks)
Jun-30-25 02:21PM	Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains (MarketBeat)
Jun-27-25 07:45AM	Why GeneDX Stock Surged Higher This Week (Motley Fool)
Jun-25-25 08:30AM	GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics (Business Wire)
Jun-24-25 04:25PM	Why GeneDx, An IBD 50 Stock, Has Skyrocketed 36% Over The Past Two Days (Investor's Business Daily) +14.04%
07:31AM	GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last? (Zacks)
Jun-23-25 03:17PM	GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability (Business Wire) +18.97%
08:30AM	Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases (Business Wire)
Jun-17-25 08:59AM	Zacks Industry Outlook Highlights CVS Health, BrightSpring Health Services and GeneDx (Zacks)
Jun-16-25 11:09AM	3 Medical Services Stocks Capitalizing on the Healthcare AI Boom (Zacks)
09:35AM	Here's Why ENSG Shares Are Attracting Prudent Investors Now (Zacks)
Jun-03-25 11:44AM	Ensign Enhances Presence With 3 New Acquisitions in 2 States (Zacks)
Jun-02-25 12:22PM	Here's Why You Should Hold Cigna Stock in Your Portfolio for Now (Zacks)
May-30-25 11:50AM	Danaher Partners With AstraZeneca to Support Precision Medicine (Zacks)
09:32AM	COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down (Zacks)
09:31AM	Here's Why You Should Add Cencora Stock to Your Portfolio Now (Zacks)
May-29-25 09:55AM	Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know (Zacks)
09:29AM	Reasons to Retain The Cooper Companies Stock in Your Portfolio Now (Zacks)
May-28-25 09:40AM	Here's Why You Should Add Pediatrix Medical to Your Portfolio Now (Zacks)
09:14AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
May-27-25 11:17AM	Here's Why Encompass Health Shares Are Attracting Investors Now (Zacks)
May-23-25 04:03PM	Here's Why You Should Retain CONMED Stock in Your Portfolio for Now (Zacks) +6.34%
07:28AM	Brookdale Shares Down 4.9% Despite Q1 Earnings Meeting Estimates (Zacks)
06:02AM	Insiders Pour Millions into These 3 Stocks Heres Why They Draw Plaudits Across the Board (TipRanks)
May-22-25 04:05PM	GeneDx to Participate in Upcoming Investor Conferences (Business Wire)
08:00AM	GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale (Business Wire)
May-21-25 07:17AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio (Zacks) -6.00%
May-19-25 07:02AM	Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now (Zacks)
May-16-25 08:00AM	Here's Why You Should Add DexCom Stock to Your Portfolio Now (Zacks) +7.39%
07:59AM	Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up (Zacks)
May-14-25 10:51AM	The Joint Misses Q1 Earnings Estimates on Rising Expenses (Zacks)
May-13-25 11:06AM	Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions (Zacks)
May-09-25 11:35AM	Pediatrix Medical's Q1 Earnings Beat Estimates on Declining Costs (Zacks)
May-08-25 12:31PM	Select Medical Lags Q1 Earnings Estimates, Lowers Revenue Outlook (Zacks)
11:39AM	TDOC Q1 Loss Narrower Than Estimates on Strong Integrated Care Unit (Zacks)
May-07-25 08:30AM	GeneDx Announces Completion of Fabric Genomics Acquisition (Business Wire) -9.37%
May-05-25 10:00AM	Best Momentum Stocks to Buy for May 5th (Zacks)
08:16AM	New Strong Buy Stocks for May 5th (Zacks)
May-02-25 04:23PM	Why Investors Were Avoiding GeneDx Holdings Stock This Week (Motley Fool) +7.88%
May-01-25 10:30AM	GeneDx earnings selloff a buying opportunity, says Craig-Hallum (TipRanks) -6.78%
Apr-30-25 04:29PM	IBD 50's GeneDx, Down 43%, Was 'Priced For Perfection.' Here's What It Missed. (Investor's Business Daily) -42.85%
01:15PM	GeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
12:28PM	Why GeneDx Holdings Stock Is Plunging Today (Motley Fool)
08:53AM	IBD 50 Stock GeneDx Hammered Despite Earnings Beat-And-Raise (Investor's Business Daily)
07:45AM	GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates (Zacks)
06:30AM	GeneDx Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
Apr-29-25 12:00PM	GENEDX HOLDINGS (WGS) Upgraded to Buy: Here's Why (Zacks)
Apr-28-25 11:13AM	GeneDx: Strengthening Leadership In Genomic Diagnostics (Seeking Alpha)
Apr-25-25 10:54AM	Meta Stock Struggles, Tries To Bottom Ahead Of Q1 Results; These Growth Stocks Look Much Stronger (Investor's Business Daily)
Apr-23-25 05:46PM	GeneDx Holdings Corp. (WGS): Among the Best Multibagger Stocks to Buy According to Billionaires (Insider Monkey) +9.08%
Apr-21-25 09:57AM	Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results? (Zacks)
Apr-18-25 08:01AM	GeneDx Holdings Corp. (WGS) Rose on Robust Customer Demand (Insider Monkey)
Apr-16-25 04:02PM	IBD 50's GeneDx Inks $51 Million AI-Tied Takeover Deal (Investor's Business Daily)
06:00AM	GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale (Business Wire)
Apr-08-25 08:05AM	GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025 (Business Wire)

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stueland Katherine	Chief Executive Officer	Sep 09 '25	Option Exercise	0.00	6,546	0	9,986	Sep 11 04:07 PM
Stueland Katherine	Chief Executive Officer	Sep 09 '25	Sale	128.06	3,657	468,297	6,329	Sep 11 04:07 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '25	Option Exercise	0.00	2,462	0	6,558	Sep 11 04:06 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 09 '25	Sale	128.05	1,272	162,886	5,286	Sep 11 04:06 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 01 '25	Option Exercise	0.00	717	0	4,474	Sep 03 06:31 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Sep 02 '25	Sale	125.81	378	47,556	4,096	Sep 03 06:31 PM
Ryan Jason	Director	Aug 27 '25	Sale	127.30	38,072	4,846,708	103,284	Aug 27 09:01 PM
Ryan Jason	Director	Aug 27 '25	Sale	129.65	1,150	149,093	11,904	Aug 27 09:01 PM
Ryan Jason	Director	Aug 27 '25	Proposed Sale	127.22	39,222	4,990,000		Aug 27 05:20 PM
Casdin Partners Master Fund, L	Affiliate	Aug 22 '25	Proposed Sale	120.90	500,000	60,451,950		Aug 22 07:14 PM
Casdin Capital, LLC	Director	Aug 22 '25	Sale	120.90	500,000	60,451,950	3,007,164	Aug 22 06:55 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '25	Option Exercise	0.00	753	0	4,145	Jul 31 04:06 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 29 '25	Sale	105.31	388	40,860	3,757	Jul 31 04:06 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '25	Option Exercise	0.00	3,874	0	5,594	Jul 31 04:04 PM
Stueland Katherine	Chief Executive Officer	Jul 29 '25	Sale	105.31	2,154	226,838	3,440	Jul 31 04:04 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 09 '25	Option Exercise	32.67	1,245	40,674	8,670	Jul 11 04:04 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 09 '25	Sale	93.00	5,278	490,854	3,392	Jul 11 04:04 PM
Stueland Katherine	Chief Executive Officer	Jul 09 '25	Sale	93.00	3,220	299,460	1,720	Jul 11 04:03 PM
Stueland Katherine	Chief Executive Officer	Jul 01 '25	Sale	90.94	9,657	878,181	4,940	Jul 03 02:32 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jul 01 '25	Sale	91.12	1,344	122,471	7,425	Jul 03 02:31 PM
Kevin Feeley	Officer	Jul 01 '25	Proposed Sale	92.32	5,805	535,900		Jul 01 07:53 PM
Katherine Stueland	Director	Jul 01 '25	Proposed Sale	92.31	16,425	1,516,200		Jul 01 07:53 PM
Casdin Eli	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	20,518	Jun 23 05:50 PM
Meister Keith A.	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	20,129	Jun 23 05:50 PM
Ryan Jason	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	13,054	Jun 23 05:48 PM
Leproust Emily M.	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	21,276	Jun 23 05:45 PM
PFENNIGER RICHARD C JR	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	41,506	Jun 23 05:45 PM
RUCH JOSHUA	Director	Jun 18 '25	Option Exercise	0.00	12,924	0	29,723	Jun 23 05:44 PM
Stueland Katherine	Chief Executive Officer	Jun 16 '25	Option Exercise	0.00	18,750	0	25,098	Jun 18 04:14 PM
Stueland Katherine	Chief Executive Officer	Jun 16 '25	Sale	64.77	10,501	680,181	14,597	Jun 18 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 16 '25	Sale	64.77	3,729	241,539	8,769	Jun 18 04:14 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 09 '25	Option Exercise	0.00	2,462	0	6,567	Jun 11 04:05 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 09 '25	Sale	72.55	1,266	91,848	5,301	Jun 11 04:05 PM
Stueland Katherine	Chief Executive Officer	Jun 09 '25	Option Exercise	0.00	6,547	0	9,987	Jun 11 04:04 PM
Stueland Katherine	Chief Executive Officer	Jun 09 '25	Sale	72.55	3,639	264,009	6,348	Jun 11 04:04 PM
Kevin Feeley	Officer	Jun 09 '25	Proposed Sale	72.55	5,009	363,400		Jun 09 07:23 PM
Katherine Stueland	Officer	Jun 09 '25	Proposed Sale	72.55	14,139	1,025,800		Jun 09 07:22 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 01 '25	Option Exercise	0.00	718	0	4,475	Jun 03 05:30 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jun 02 '25	Sale	71.26	370	26,366	4,105	Jun 03 05:30 PM
Kevin Feeley	Officer	Jun 02 '25	Proposed Sale	71.35	370	26,400		Jun 02 08:55 PM
Meister Keith A.	Director	May 14 '25	Buy	60.16	50,000	3,007,997	3,058,629	May 16 04:00 PM
Meister Keith A.	Director	May 08 '25	Buy	56.01	100,000	5,600,994	3,008,629	May 12 07:46 PM
PFENNIGER RICHARD C JR	Director	May 02 '25	Option Exercise	0.00	918	0	28,582	May 05 04:48 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '25	Option Exercise	0.00	753	0	3,725	May 01 07:46 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 29 '25	Sale	113.09	388	43,879	3,337	May 01 07:46 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '25	Option Exercise	0.00	3,874	0	5,594	May 01 07:44 PM
Stueland Katherine	Chief Executive Officer	Apr 29 '25	Sale	113.09	2,154	243,596	3,440	May 01 07:44 PM
Kevin Feeley	Officer	Apr 29 '25	Proposed Sale	113.14	388	43,900		Apr 29 09:52 PM
Katherine Stueland	Director	Apr 29 '25	Proposed Sale	113.09	2,154	243,600		Apr 29 09:51 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Apr 14 '25	Proposed Sale	101.04	250,000	25,260,000		Apr 14 08:00 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 09 '25	Option Exercise	32.67	1,246	40,707	17,242	Apr 10 04:12 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Apr 09 '25	Sale	92.18	15,516	1,430,334	1,726	Apr 10 04:12 PM
Stueland Katherine	Chief Executive Officer	Apr 09 '25	Sale	89.62	46,594	4,175,817	1,720	Apr 10 04:11 PM
Feeley Kevin	Officer	Apr 09 '25	Proposed Sale	91.80	14,270	1,310,000		Apr 09 05:36 PM
Stueland Katherine	Officer	Apr 09 '25	Proposed Sale	87.99	46,594	4,100,000		Apr 09 05:10 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 26 '25	Option Exercise	0.00	16,250	0	24,742	Mar 28 04:07 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 26 '25	Sale	95.61	8,746	836,211	15,996	Mar 28 04:07 PM
Stueland Katherine	Chief Executive Officer	Mar 26 '25	Option Exercise	0.00	80,000	0	94,865	Mar 28 04:07 PM
Stueland Katherine	Chief Executive Officer	Mar 26 '25	Sale	95.62	46,551	4,451,084	48,314	Mar 28 04:07 PM
Kevin Feeley	Officer	Mar 26 '25	Proposed Sale	95.61	8,746	836,200		Mar 26 06:36 PM
Katherine Stueland	Director	Mar 26 '25	Proposed Sale	95.62	46,551	4,451,200		Mar 26 06:34 PM
Stueland Katherine	Chief Executive Officer	Mar 16 '25	Option Exercise	0.00	18,750	0	25,424	Mar 17 09:51 PM
Stueland Katherine	Chief Executive Officer	Mar 17 '25	Sale	96.71	10,559	1,021,146	14,865	Mar 17 09:51 PM
Stueland Katherine	Chief Executive Officer	Mar 13 '25	Sale	89.44	1,078	96,420	6,674	Mar 17 09:51 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 17 '25	Sale	96.71	3,749	362,565	8,492	Mar 17 09:50 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 13 '25	Sale	90.05	402	36,202	5,044	Mar 17 09:50 PM
Kevin Feeley	Officer	Mar 17 '25	Proposed Sale	96.72	3,749	362,600		Mar 17 06:46 PM
Katherine Stueland	Director	Mar 17 '25	Proposed Sale	96.70	10,559	1,021,100		Mar 17 06:44 PM
Kevin Feeley	Officer	Mar 13 '25	Proposed Sale	90.05	402	36,200		Mar 13 07:04 PM
Katherine Stueland	Officer	Mar 13 '25	Proposed Sale	89.42	1,078	96,400		Mar 13 07:03 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 09 '25	Option Exercise	0.00	2,462	0	6,368	Mar 11 05:42 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 10 '25	Sale	94.72	922	87,334	5,446	Mar 11 05:42 PM
Stueland Katherine	Chief Executive Officer	Mar 09 '25	Option Exercise	0.00	6,546	0	10,483	Mar 11 05:40 PM
Stueland Katherine	Chief Executive Officer	Mar 10 '25	Sale	94.73	2,731	258,695	7,752	Mar 11 05:40 PM
Kevin Feeley	Officer	Mar 10 '25	Proposed Sale	94.69	922	87,300		Mar 10 07:44 PM
Katherine Stueland	Officer	Mar 10 '25	Proposed Sale	94.73	2,731	258,700		Mar 10 07:43 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 01 '25	Option Exercise	0.00	717	0	4,167	Mar 04 04:36 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Mar 03 '25	Sale	103.94	261	27,128	3,906	Mar 04 04:36 PM
Kevin Feeley	Officer	Mar 03 '25	Proposed Sale	103.83	261	27,100		Mar 03 06:59 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Feb 24 '25	Proposed Sale	95.83	373,569	35,799,117		Feb 24 08:00 PM
RUCH JOSHUA	Director	Feb 05 '25	Option Exercise	7.89	5,816	45,888	16,799	Feb 07 04:01 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 29 '25	Option Exercise	0.00	753	0	3,225	Jan 31 05:47 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 29 '25	Sale	78.48	275	21,582	2,950	Jan 31 05:47 PM
Stueland Katherine	Chief Executive Officer	Jan 29 '25	Option Exercise	0.00	3,874	0	5,594	Jan 31 05:46 PM
Stueland Katherine	Chief Executive Officer	Jan 29 '25	Sale	78.48	1,657	130,046	3,937	Jan 31 05:46 PM
ICAHN SCHOOL OF MEDICINE AT MO	Stockholder	Jan 30 '25	Proposed Sale	77.86	1,346,123	104,809,137		Jan 30 08:02 PM
Kevin Feeley	Officer	Jan 29 '25	Proposed Sale	78.55	275	21,600		Jan 29 09:06 PM
Katherine Stueland	Director	Jan 29 '25	Proposed Sale	78.46	1,657	130,000		Jan 29 09:04 PM
RUCH JOSHUA	Director	Jan 17 '25	Option Exercise	7.89	3,000	23,670	10,983	Jan 22 05:08 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 07 '25	Option Exercise	32.67	11,208	366,165	37,978	Jan 10 05:54 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 07 '25	Sale	93.82	35,506	3,331,024	2,472	Jan 10 05:54 PM
Stueland Katherine	Chief Executive Officer	Jan 07 '25	Sale	94.48	51,420	4,858,119	1,720	Jan 10 05:53 PM
Feeley Kevin	Officer	Jan 07 '25	Proposed Sale	94.07	35,506	3,340,000		Jan 07 05:02 PM
Stueland Katherine	Officer	Jan 07 '25	Proposed Sale	93.93	51,420	4,830,000		Jan 07 04:44 PM
Stueland Katherine	Chief Executive Officer	Jan 02 '25	Sale	78.18	18,006	1,407,686	53,140	Jan 06 06:05 PM
Feeley Kevin	CHIEF FINANCIAL OFFICER	Jan 02 '25	Sale	76.04	1,430	108,737	26,770	Jan 06 06:04 PM
Feeley Kevin	Officer	Jan 02 '25	Proposed Sale	75.52	1,430	108,000		Jan 02 05:03 PM
Stueland Katherine	Officer	Jan 02 '25	Proposed Sale	77.75	18,006	1,400,000		Jan 02 04:31 PM
Stueland Katherine	Chief Executive Officer	Dec 16 '24	Option Exercise	0.00	18,750	0	81,647	Dec 18 06:22 PM
Stueland Katherine	Chief Executive Officer	Dec 16 '24	Sale	76.75	10,501	805,995	71,146	Dec 18 06:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

WGS

GeneDx Holdings Corp

Upgrade your FINVIZ experience